---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-009789"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T09:02:57.132900+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tivic reports FY2025 net loss $8.8M-$9.1M; pivots to immunotherapy with Entolimod

## Summary
- Operating expenses $7.9M in 2025 vs $4.5M in 2024; net loss before disc. ops $7.9M-$8.1M.
- Cash $12.6M at Dec 31, 2025 vs $2.0M at prior year-end; working capital $12.4M.
- Acquired global rights to Entolimod for acute radiation syndrome; discontinued ClearUP/VNS.
- CEO Michael K. Handley appointed March 2026, succeeding Jennifer Ernst.
- Engaged with BARDA, DTRA, NIH, NIAID for potential Entolimod funding or procurement.

## SEC filing metadata
- accession: 0001437749-26-009789
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000143774926009789/0001437749-26-009789-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000143774926009789/tivc20251119_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-009789
- JSON: https://secwatch.observer/filing/0001437749-26-009789.json
- Plain text: https://secwatch.observer/filing/0001437749-26-009789.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.